Patients with objective responses in this study had tumors that did not universally harbor the prognostically favorable mutation in IDH1 and had both MGMT methylated and unmethylated tumors, representing the group of glioblastomas that desperately need efficacious therapies. Here, IDH1 is linked to glioblastoma.